Literature DB >> 26633544

The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data.

Daniel F Wallace1,2, V Nathan Subramaniam1,2.   

Abstract

PURPOSE: The prevalence of HFE-related hereditary hemochromatosis (HH) among European populations has been well studied. There are no prevalence data for atypical forms of HH caused by mutations in HFE2, HAMP, TFR2, or SLC40A1. The purpose of this study was to estimate the population prevalence of these non-HFE forms of HH.
METHODS: A list of HH pathogenic variants in publically available next-generation sequence (NGS) databases was compiled and allele frequencies were determined.
RESULTS: Of 161 variants previously associated with HH, 43 were represented among the NGS data sets; an additional 40 unreported functional variants also were identified. The predicted prevalence of HFE HH and the p.Cys282Tyr mutation closely matched previous estimates from similar populations. Of the non-HFE forms of iron overload, TFR2-, HFE2-, and HAMP-related forms are predicted to be rare, with pathogenic allele frequencies in the range of 0.00007 to 0.0005. Significantly, SLC40A1 variants that have been previously associated with autosomal-dominant ferroportin disease were identified in several populations (pathogenic allele frequency 0.0004), being most prevalent among Africans.
CONCLUSION: We have, for the first time, estimated the population prevalence of non-HFE HH. This methodology could be applied to estimate the population prevalence of a wide variety of genetic disorders.Genet Med 18 6, 618-626.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26633544     DOI: 10.1038/gim.2015.140

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  40 in total

1.  Global prevalence of putative haemochromatosis mutations.

Authors:  A T Merryweather-Clarke; J J Pointon; J D Shearman; K J Robson
Journal:  J Med Genet       Date:  1997-04       Impact factor: 6.318

2.  Autosomal dominant hereditary hemochromatosis associated with two novel Ferroportin 1 mutations in Spain.

Authors:  V Bach; A Remacha; A Altés; M J Barceló; M A Molina; M Baiget
Journal:  Blood Cells Mol Dis       Date:  2005-10-27       Impact factor: 3.039

3.  Mutations in the HFE, TFR2, and SLC40A1 genes in patients with hemochromatosis.

Authors:  Alejandro Del-Castillo-Rueda; María-Isabel Moreno-Carralero; Nuria Cuadrado-Grande; Luis-Antonio Alvarez-Sala-Walther; Rafael Enríquez-de-Salamanca; Manuel Méndez; María-Josefa Morán-Jiménez
Journal:  Gene       Date:  2012-08-04       Impact factor: 3.688

4.  Comprehensive functional annotation of 18 missense mutations found in suspected hemochromatosis type 4 patients.

Authors:  Isabelle Callebaut; Rozenn Joubrel; Serge Pissard; Caroline Kannengiesser; Victoria Gérolami; Cécile Ged; Estelle Cadet; François Cartault; Chandran Ka; Isabelle Gourlaouen; Lénaick Gourhant; Claire Oudin; Michel Goossens; Bernard Grandchamp; Hubert De Verneuil; Jacques Rochette; Claude Férec; Gérald Le Gac
Journal:  Hum Mol Genet       Date:  2014-04-08       Impact factor: 6.150

5.  Penetrance of 845G--> A (C282Y) HFE hereditary haemochromatosis mutation in the USA.

Authors:  Ernest Beutler; Vincent J Felitti; James A Koziol; Ngoc J Ho; Terri Gelbart
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

6.  A European allele map of the C282Y mutation of hemochromatosis: Celtic versus Viking origin of the mutation?

Authors:  Gérard Lucotte; Florent Dieterlen
Journal:  Blood Cells Mol Dis       Date:  2003 Sep-Oct       Impact factor: 3.039

7.  SLC40A1 c.1402G-->a results in aberrant splicing, ferroportin truncation after glycine 330, and an autosomal dominant hemochromatosis phenotype.

Authors:  Pauline L Lee; Terri Gelbart; Carol West; James C Barton
Journal:  Acta Haematol       Date:  2007-12-21       Impact factor: 2.195

Review 8.  Non-HFE haemochromatosis.

Authors:  Daniel-F Wallace; V-Nathan Subramaniam
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

9.  Population screening for hemochromatosis: a study in 5370 Spanish blood donors.

Authors:  Mayka Sánchez; Margarita Villa; Mercedes Ingelmo; Cristina Sanz; Miquel Bruguera; Carlos Ascaso; Rafael Oliva
Journal:  J Hepatol       Date:  2003-06       Impact factor: 25.083

10.  Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis.

Authors:  Antonella Roetto; George Papanikolaou; Marianna Politou; Federica Alberti; Domenico Girelli; John Christakis; Dimitris Loukopoulos; Clara Camaschella
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

View more
  14 in total

Review 1.  The Regulation of Iron Absorption and Homeostasis.

Authors:  Daniel F Wallace
Journal:  Clin Biochem Rev       Date:  2016-05

Review 2.  Ethnic Differences in Iron Status.

Authors:  Wanhui Kang; Alexa Barad; Andrew G Clark; Yiqin Wang; Xu Lin; Zhenglong Gu; Kimberly O O'Brien
Journal:  Adv Nutr       Date:  2021-10-01       Impact factor: 8.701

3.  Variation in the repulsive guidance molecule family in human populations.

Authors:  Peter Rotwein
Journal:  Physiol Rep       Date:  2019-02

Review 4.  Genotypic and phenotypic spectra of hemojuvelin mutations in primary hemochromatosis patients: a systematic review.

Authors:  Xiaomu Kong; Lingding Xie; Haiqing Zhu; Lulu Song; Xiaoyan Xing; Wenying Yang; Xiaoping Chen
Journal:  Orphanet J Rare Dis       Date:  2019-07-08       Impact factor: 4.123

5.  A case report of hereditary hemochromatosis caused by mutation of SLC40A1 gene.

Authors:  Xin Yin; Yu Zhang; Hui Gao; Qing-Long Jin; Xiao-Yu Wen
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

6.  Genetic diagnosis history and osteoarticular phenotype of a non-transfusion secondary hemochromatosis.

Authors:  Dan-Dan Ruan; Yu-Mian Gan; Tao Lu; Xiao Yang; Yao-Bin Zhu; Qing-Hua Yu; Li-Sheng Liao; Ning Lin; Xin Qian; Jie-Wei Luo; Fa-Qiang Tang
Journal:  World J Clin Cases       Date:  2020-12-06       Impact factor: 1.337

7.  Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report.

Authors:  Shamil D Cooray; Neel M Heerasing; Laura A Selkrig; V Nathan Subramaniam; P Shane Hamblin; Cameron J McDonald; Catriona A McLean; Elissa McNamara; Angeline S Leet; Stuart K Roberts
Journal:  J Med Case Rep       Date:  2018-01-26

Review 8.  Ferroportin disease: pathogenesis, diagnosis and treatment.

Authors:  Antonello Pietrangelo
Journal:  Haematologica       Date:  2017-11-03       Impact factor: 9.941

9.  The SLC40A1 R178Q mutation is a recurrent cause of hemochromatosis and is associated with a novel pathogenic mechanism.

Authors:  Chandran Ka; Julie Guellec; Xavier Pepermans; Caroline Kannengiesser; Cécile Ged; Wim Wuyts; David Cassiman; Victor de Ledinghen; Bruno Varet; Caroline de Kerguenec; Claire Oudin; Isabelle Gourlaouen; Thibaud Lefebvre; Claude Férec; Isabelle Callebaut; Gérald Le Gac
Journal:  Haematologica       Date:  2018-07-12       Impact factor: 9.941

10.  Clinical Penetrance of Hereditary Hemochromatosis-Related End-Organ Damage of C282Y Homozygosity, A Newfoundland Experience.

Authors:  Dennis R Lim; Gokul Vidyasankar; Chai Phua; Mark Borgaonkar
Journal:  Clin Transl Gastroenterol       Date:  2020-11       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.